Fengtao You
Overview
Explore the profile of Fengtao You including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang L, You F, Wu H, Qi C, Xiang S, Zhang P, et al.
Cancer Res
. 2024 Sep;
84(23):4066-4080.
PMID: 39240694
Vδ1T cells, a rare subset of γδT cells, hold promise for treating solid tumors. Unlike conventional T cells, they recognize tumor antigens independently of the MHC antigen presentation pathway, making...
2.
Ma R, You F, Tian S, Zhang T, Tian X, Xiang S, et al.
Eur J Haematol
. 2023 Sep;
112(1):64-74.
PMID: 37671595
Objectives: Despite the great success of CD19 CAR-T cell therapy, its clinical efficacy has been greatly hampered by the high relapse rate. In this study, we designed and compared four...
3.
Wang T, Zhang K, You F, Ma R, Yang N, Tian S, et al.
Life Sci
. 2023 Aug;
331:122024.
PMID: 37574043
Aims: Limited efficacy of chimeric antigen receptor T (CAR-T) cells in treating solid tumors is largely due to the antigen heterogeneity and immunosuppressive tumor microenvironment (TME). B7-H3 is over-expressed in...
4.
Sheng B, Zhang K, Tian S, Ma R, Li Z, Wu H, et al.
Heliyon
. 2023 Jul;
9(6):e16961.
PMID: 37416646
CD7 protein as a target is being used to treat CD7 lymphoma; however, the role of CD7 in the hematopoietic system remains largely unknown. Therefore, we evaluated the effects of...
5.
Fan S, Wang T, You F, Zhang T, Li Y, Ji C, et al.
Eur J Med Res
. 2023 Mar;
28(1):129.
PMID: 36941687
Background And Aims: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of immunotherapy. However, the use of CAR-T cells to treat acute myeloid leukaemia (AML) has limitations. B7-H3...
6.
Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al.
Clin Cancer Res
. 2022 Apr;
28(13):2830-2843.
PMID: 35435984
Purpose: Since CD7 may represent a potent target for T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) immunotherapy, this study aimed to investigate safety and efficacy of autologous CD7-chimeric antigen receptor (CAR) T cells in...
7.
Zhang T, Wang T, You F, Li Z, Chen D, Zhang K, et al.
Transpl Immunol
. 2022 Jan;
71:101538.
PMID: 35051588
Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 can achieve impressive clinical remission rates in the treatment of B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. However, relapse after CD19-CAR...
8.
Chen D, You F, Xiang S, Wang Y, Li Y, Meng H, et al.
Am J Cancer Res
. 2021 Dec;
11(11):5263-5281.
PMID: 34873460
The great success of chimeric antigen receptor T (CAR-T)-cell therapy in B-cell malignancies has significantly promoted its rapid expansion to other targets and indications, including T-cell malignancies and acute myeloid...
9.
Zhai X, You F, Xiang S, Jiang L, Chen D, Li Y, et al.
Am J Cancer Res
. 2021 Feb;
11(1):79-91.
PMID: 33520361
Chimeric antigen receptor (CAR) αβ T cell adoptive immunotherapy has shown great promise for improving cancer treatment. However, there are several hurdles to overcome for the wide clinical application of...
10.
Li S, Xue L, Wang M, Qiang P, Xu H, Zhang X, et al.
Onco Targets Ther
. 2019 Aug;
12:5627-5638.
PMID: 31372000
CD19-directed chimeric antigen receptor (CAR) T cells have substantial benefit in the treatment of patients with B-cell malignancies. However, despite encouraging therapeutic efficiency, there is limited overall response rate when...